AstraZeneca’s new antibody therapy reduced the risk of people developing Covid-19 symptoms by 77% in a late-stage trial, putting the drugmaker on track to offer protection
AstraZeneca’s new antibody therapy reduced the risk of people developing Covid-19 symptoms by 77% in a late-stage trial, putting the drugmaker on track to offer protection